These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 9207368)
1. Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers. Sack DA; Sack RB; Shimko J; Gomes G; O'Sullivan D; Metcalfe K; Spriggs D J Infect Dis; 1997 Jul; 176(1):201-5. PubMed ID: 9207368 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Taylor DN; Tacket CO; Losonsky G; Castro O; Gutierrez J; Meza R; Nataro JP; Kaper JB; Wasserman SS; Edelman R; Levine MM; Cryz SJ Infect Immun; 1997 Sep; 65(9):3852-6. PubMed ID: 9284163 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae. Chen WH; Garza J; Choquette M; Hawkins J; Hoeper A; Bernstein DI; Cohen MB Clin Vaccine Immunol; 2015 Jan; 22(1):129-35. PubMed ID: 25410205 [TBL] [Abstract][Full Text] [Related]
4. Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers. Sack DA; Shimko J; Sack RB; Gomes JG; MacLeod K; O'Sullivan D; Spriggs D Infect Immun; 1997 Jun; 65(6):2107-11. PubMed ID: 9169739 [TBL] [Abstract][Full Text] [Related]
5. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Suharyono ; Simanjuntak C; Witham N; Punjabi N; Heppner DG; Losonsky G; Totosudirjo H; Rifai AR; Clemens J; Lim YL Lancet; 1992 Sep; 340(8821):689-94. PubMed ID: 1355798 [TBL] [Abstract][Full Text] [Related]
7. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Perry RT; Plowe CV; Koumaré B; Bougoudogo F; Kotloff KL; Losonsky GA; Wasserman SS; Levine MM Bull World Health Organ; 1998; 76(1):63-71. PubMed ID: 9615498 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia. Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522 [TBL] [Abstract][Full Text] [Related]
9. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. Qadri F; Chowdhury MI; Faruque SM; Salam MA; Ahmed T; Begum YA; Saha A; Alam MS; Zaman K; Seidlein LV; Park E; Killeen KP; Mekalanos JJ; Clemens JD; Sack DA; J Infect Dis; 2005 Aug; 192(4):573-9. PubMed ID: 16028125 [TBL] [Abstract][Full Text] [Related]
10. Peru-15 (Choleragarde(®)), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand. Ratanasuwan W; Kim YH; Sah BK; Suwanagool S; Kim DR; Anekthananon A; Lopez AL; Techasathit W; Grahek SL; Clemens JD; Wierzba TF Vaccine; 2015 Sep; 33(38):4820-6. PubMed ID: 26241948 [TBL] [Abstract][Full Text] [Related]
11. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Cohen MB; Giannella RA; Bean J; Taylor DN; Parker S; Hoeper A; Wowk S; Hawkins J; Kochi SK; Schiff G; Killeen KP Infect Immun; 2002 Apr; 70(4):1965-70. PubMed ID: 11895960 [TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults. Valera R; García HM; Jidy MD; Mirabal M; Armesto MI; Fando R; García L; Fernández R; Año G; Cedré B; Ramírez M; Bravo L; Serrano T; Palma S; González D; Miralles F; Medina V; Nuñez F; Plasencia Y; Martínez JC; Mandarioti A; Lugones J; Rodríguez BL; Moreno A; González D; Baro M; Solis RL; Sierra G; Barbera R; Domínguez F; Gutiérrez C; Kouri G; Campa C; Menéndez J Vaccine; 2009 Nov; 27(47):6564-9. PubMed ID: 19720365 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. Chen WH; Greenberg RN; Pasetti MF; Livio S; Lock M; Gurwith M; Levine MM Clin Vaccine Immunol; 2014 Jan; 21(1):66-73. PubMed ID: 24173028 [TBL] [Abstract][Full Text] [Related]
14. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Migasena S; Pitisuttitham P; Prayurahong B; Suntharasamai P; Supanaranond W; Desakorn V; Vongsthongsri U; Tall B; Ketley J; Losonsky G Infect Immun; 1989 Nov; 57(11):3261-4. PubMed ID: 2807523 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45. McCarty JM; Lock MD; Hunt KM; Simon JK; Gurwith M Vaccine; 2018 Feb; 36(6):833-840. PubMed ID: 29317118 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Kotloff KL; Wasserman SS; O'Donnell S; Losonsky GA; Cryz SJ; Levine MM Infect Immun; 1992 Oct; 60(10):4430-2. PubMed ID: 1398956 [TBL] [Abstract][Full Text] [Related]
17. Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years. McCarty JM; Gierman EC; Bedell L; Lock MD; Bennett S Am J Trop Med Hyg; 2020 Jan; 102(1):48-57. PubMed ID: 31769402 [TBL] [Abstract][Full Text] [Related]
18. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Qadri F; Chowdhury MI; Faruque SM; Salam MA; Ahmed T; Begum YA; Saha A; Al Tarique A; Seidlein LV; Park E; Killeen KP; Mekalanos JJ; Clemens JD; Sack DA; Vaccine; 2007 Jan; 25(2):231-8. PubMed ID: 16996172 [TBL] [Abstract][Full Text] [Related]
19. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804 [TBL] [Abstract][Full Text] [Related]
20. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Gotuzzo E; Butron B; Seas C; Penny M; Ruiz R; Losonsky G; Lanata CF; Wasserman SS; Salazar E; Kaper JB Infect Immun; 1993 Sep; 61(9):3994-7. PubMed ID: 8359923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]